JPMorgan analyst Jeffrey Zekauskas lowered the firm’s price target on Scotts Miracle-Gro (SMG) to $65 from $80 and keeps an Overweight rating on the shares. The firm reduced EBITDA estimates post the Q1 report. It cites lower trading multiples in a period of greater economic risk for the target cut.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SMG:
- Scotts Miracle-Gro Reports Q2 2025 Financial Results
- Scotts Miracle-Gro Earnings Call: Optimism Amid Challenges
- Scotts Miracle-Gro price target lowered to $62 from $69 at Jefferies
- Scotts Miracle-Gro: Strong Cost Management and Positive Outlook Lead to Buy Rating
- Scotts Miracle-Gro reports Q2 adjusted EPS $3.98, consensus $3.93